CLCNKA/CLCNKB Antibody (C-term) Blocking peptide
Synthetic peptide
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | P51801 |
---|---|
Clone Names | 2022201 |
Gene ID | 1188 |
---|---|
Other Names | Chloride channel protein ClC-Kb, Chloride channel Kb, ClC-K2, CLCNKB |
Target/Specificity | The synthetic peptide sequence used to generate the antibody AP6358a was selected from the C-term region of human CLCNKB. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay. |
Format | Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed. |
Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. |
Precautions | This product is for research use only. Not for use in diagnostic or therapeutic procedures. |
Name | CLCNKB |
---|---|
Function | Voltage-gated chloride channel. Chloride channels have several functions including the regulation of cell volume; membrane potential stabilization, signal transduction and transepithelial transport. May be important in urinary concentrating mechanisms. |
Cellular Location | Cell membrane; Multi-pass membrane protein. |
Tissue Location | Expressed predominantly in the kidney. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Chloride channel Kb (CLCNKB) is a member of the CLC family of voltage-gated chloride channels, which comprises at least 9 mammalian chloride channels. Each is believed to have 12 transmembrane domains and intracellular N and C termini. Mutations in CLCNKB result in the autosomal recessive Type III Bartter Syndrome. CLCNKA and CLCNKB are closely related (94% sequence identity), tightly linked (separated by 11 kb of genomic sequence) and are both expressed in mammalian kidney.
References
Schlingmann, K.P., et al., N. Engl. J. Med. 350(13):1314-1319 (2004).Jeck, N., et al., Kidney Int. 65(1):190-197 (2004).Maehara, H., et al., Neuroreport 14(12):1571-1573 (2003).Zelikovic, I., et al., Kidney Int. 63(1):24-32 (2003).Colussi, G., et al., Nephrol. Dial. Transplant. 17(3):521-523 (2002).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.